MX2024003333A - Terapia de triple agente para el tratamiento de cáncer. - Google Patents
Terapia de triple agente para el tratamiento de cáncer.Info
- Publication number
- MX2024003333A MX2024003333A MX2024003333A MX2024003333A MX2024003333A MX 2024003333 A MX2024003333 A MX 2024003333A MX 2024003333 A MX2024003333 A MX 2024003333A MX 2024003333 A MX2024003333 A MX 2024003333A MX 2024003333 A MX2024003333 A MX 2024003333A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- treatment
- treatment regimen
- cancer treatment
- metronomic
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 7
- 201000011510 cancer Diseases 0.000 title abstract 7
- 238000011282 treatment Methods 0.000 title abstract 4
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 abstract 6
- 238000011269 treatment regimen Methods 0.000 abstract 5
- 239000005411 L01XE02 - Gefitinib Substances 0.000 abstract 3
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 abstract 3
- 229960002584 gefitinib Drugs 0.000 abstract 3
- 229960001603 tamoxifen Drugs 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 abstract 2
- 229960002066 vinorelbine Drugs 0.000 abstract 2
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940041181 antineoplastic drug Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163244412P | 2021-09-15 | 2021-09-15 | |
| PCT/US2022/043601 WO2023043883A1 (en) | 2021-09-15 | 2022-09-15 | Triple-agent therapy for cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024003333A true MX2024003333A (es) | 2024-05-20 |
Family
ID=85603487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024003333A MX2024003333A (es) | 2021-09-15 | 2022-09-15 | Terapia de triple agente para el tratamiento de cáncer. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12611411B2 (https=) |
| EP (1) | EP4401720A4 (https=) |
| JP (1) | JP2024531765A (https=) |
| KR (1) | KR20240060625A (https=) |
| CN (1) | CN118159262A (https=) |
| AU (1) | AU2022345084A1 (https=) |
| CA (1) | CA3231639A1 (https=) |
| IL (1) | IL311229A (https=) |
| MX (1) | MX2024003333A (https=) |
| WO (1) | WO2023043883A1 (https=) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2644194T3 (en) * | 2008-03-18 | 2017-07-03 | Genentech Inc | Combinations of an anti-HER2 antibody-drug conjugate and docetaxel |
| US20100189683A1 (en) | 2008-11-14 | 2010-07-29 | Ascenta Therapeutics, Inc. | Pulsatile Dosing of Gossypol for Treatment of Disease |
| KR101874390B1 (ko) * | 2013-09-26 | 2018-07-04 | 파이브3 제노믹스, 엘엘씨 | 바이러스-연관 종양을 위한 시스템, 방법, 및 조성물 |
-
2022
- 2022-09-15 MX MX2024003333A patent/MX2024003333A/es unknown
- 2022-09-15 US US18/689,980 patent/US12611411B2/en active Active
- 2022-09-15 WO PCT/US2022/043601 patent/WO2023043883A1/en not_active Ceased
- 2022-09-15 EP EP22870665.1A patent/EP4401720A4/en active Pending
- 2022-09-15 CN CN202280069063.5A patent/CN118159262A/zh active Pending
- 2022-09-15 IL IL311229A patent/IL311229A/en unknown
- 2022-09-15 KR KR1020247010862A patent/KR20240060625A/ko active Pending
- 2022-09-15 JP JP2024516808A patent/JP2024531765A/ja active Pending
- 2022-09-15 CA CA3231639A patent/CA3231639A1/en active Pending
- 2022-09-15 AU AU2022345084A patent/AU2022345084A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024531765A (ja) | 2024-08-29 |
| CA3231639A1 (en) | 2023-03-23 |
| EP4401720A4 (en) | 2025-07-30 |
| CN118159262A (zh) | 2024-06-07 |
| IL311229A (en) | 2024-05-01 |
| US20250127791A1 (en) | 2025-04-24 |
| WO2023043883A1 (en) | 2023-03-23 |
| US12611411B2 (en) | 2026-04-28 |
| AU2022345084A1 (en) | 2024-03-28 |
| EP4401720A1 (en) | 2024-07-24 |
| KR20240060625A (ko) | 2024-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021023901A2 (pt) | Conjugado anticorpo-fármaco anti-trop2, composição farmacêutica, método para tratar ou prevenir câncer, e, uso de um conjugado anticorpo-fármaco anti-trop2 na fabricação de um fármaco para o tratamento ou prevenção do câncer | |
| MX2018003698A (es) | Terapia adjuntiva con 25-hidroxi vitamina d y articulos de los mismos. | |
| CL2018000706A1 (es) | Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer. | |
| CR20170085A (es) | Terapia adjuntiva con 25-hidroxi vitamina d | |
| CO2019001537A2 (es) | Sistema y método para terapia médica controlada | |
| AR107871A1 (es) | Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos | |
| BR112018072560A2 (pt) | terapia de combinação para tratamento do câncer | |
| BR112017006113A8 (pt) | usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits. | |
| MX391719B (es) | Agentes de quimioembolizacion. | |
| CO2023001561A2 (es) | Combinaciones para el tratamiento de cáncer | |
| MX2018016332A (es) | Quimioterapias de combinacion. | |
| BR112018013896A2 (pt) | formulações para o tratamento do câncer de bexiga | |
| MX2019003134A (es) | Terapia de combinacion. | |
| MX2022014792A (es) | Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. | |
| MX377118B (es) | C. novyi para el tratamiento de tumores solidos en humanos. | |
| ECSP21031200A (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
| CL2024002763A1 (es) | Dosificación no lineal de mirdametinib | |
| MX2024003918A (es) | Agente terapeutico que induce citotoxicidad para usarse en terapia del cancer. | |
| MX2023004156A (es) | Terapia combinada para el tratamiento del cancer. | |
| MX2018013873A (es) | Irinotecan nanoliposomico para usarse en el tratamiento del cancer de pulmon de celulas pequeñas. | |
| CL2025001129A1 (es) | Anticuerpo anti-ttr; y su uso para tratar amiloidosis de transtiretina. | |
| BR112021017957A2 (pt) | Derivado tienoeterocíclico, método de preparação do mesmo e uso médico do mesmo | |
| MX2024003333A (es) | Terapia de triple agente para el tratamiento de cáncer. | |
| PY1944026A (es) | Ácido ascórbico y compuestos quinona en combinación con un agente antiparasitario para tratar enfermedades parasitarias | |
| MX2021014523A (es) | Metodos para tratar colangiocarcinoma. |